CASE REPORT

A Case Report of Dapagliflozin-Induced Nodular Vasculitis
Dapagliflozin İlişkili Nodüler Vaskülit Olgu Sunumu
Received Date : 25 Nov 2020
Accepted Date : 02 Feb 2021
Available Online : 09 Mar 2021
Doi: 10.25179/tjem.2020-80188 - Makale Dili: EN
Turk J Endocrinol Metab. 2021;25:129-132
Bu makale, CC BY-NC-SA altında lisanslanmış açık erişim bir makaledir.
ABSTRACT
Nodular vasculitis (NV), first described by Montgomery in 1945 for erythema induratum-like lesions, is a rare form of panniculitis that is particularly localized on the calves. Characterized by plaques and erythematous nodules, NV may often show ulceration and draining. It is known as a reactive disease associated with many causative factors. Several NV cases due to infectious or non-infectious causative factors have been reported, but no case of NV due to sodium-glucose cotransporter-2 inhibitors (SGLT2i) has yet been reported. In this case report, we presented a case diagnosed with NV, who presented with tender, erythematous, eroded plaques with hemorrhagic-purulent discharge on both legs during treatment with dapagliflozin (an SGLT2i).
ÖZET
İlk olarak 1945 yılında Montgomery tarafından eritema induratum benzeri lezyonlar için tanımlanmış olan nodüler vaskülit (NV), özellikle bacaklarda lokalize olan ve nadir görülen bir pannikülit formudur. NV, plaklarla ve eritematöz nodüllerle karakterize olup, zaman zaman ülsere ve akıntılı hâle gelebilir. Birçok nedensel faktörlerle ilişkili reaktif bir hastalık olarak bilinmektedir. Enfeksiyöz ya da enfeksiyöz olmayan nedenlere bağlı birçok NV vakası bildirilmiştir, ancak sodyum glukoz ko-transporter 2 (SGLT2) inhibitörlerine bağlı bir NV vakası henüz bildirilmemiştir. Bu olgu sunumunda, dapagliflozin (bir SGLT2 inhibitörü) tedavisi esnasında her iki bacağında gelişen hassas, eritemli, erode ve hemorajik-pürülan akıntılı plaklarla başvuran ve NV tanısı konulan bir olguyu sunduk.
KAYNAKLAR
  1. Montgomery RM. A case for diagnosis; dermatophytosis; nodular vasculitis? Arch Derm Syphilol. 1948;57:580.[Crossref] [PubMed] 
  2. Segura S, Pujol RM, Trindade F, Requena L. Vasculitis in erythema induratum of Bazin: a histopathologic study of 101 biopsy specimens from 86 patients. J Am Acad Dermatol. 2008;59:839-851.[Crossref] [PubMed] 
  3. Patterson JW, Brown PC, Broecker AH. Infection-induced panniculitis. J Cutan Pathol. 1989;16:183-193.[Crossref] [PubMed] 
  4. Sakuma H, Niiyama S, Amoh Y, Katsuoka K. Chlamydophila pneumoniae infection induced nodular vasculitis. Case Rep Dermatol. 2011;3:263-267.[Crossref] [PubMed] [PMC] 
  5. Ural I, Erel A, Ozenirler S, Tekin NS, Gurert MA. Nodular vasculitis associated with chronic hepatitis C. J Eur Acad Dermatol Venereol. 2002;16:298-299.[Crossref] [PubMed] 
  6. Park SB, Chang IK, Im M, Lee Y, Kim CD, Seo YJ, Lee JH. Nodular vasculitis that developed during etanercept (Enbrel) treatment in a patient with psoriasis. Ann Dermatol. 2015;27:605-607.[Crossref] [PubMed] [PMC] 
  7. Wolf D, Ben-Yehuda A, Okon E, Naparstek Y. Nodular vasculitis associated with propylthiouracil therapy. Cutis. 1992;49:253-255.[PubMed] 
  8. Misago N, Narisawa Y. Erythema induratum (nodular vasculitis) associated with Crohn's disease: a rare type of metastatic Crohn's disease. Am J Dermatopathol. 2012;34:325-329.[Crossref] [PubMed] 
  9. Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management. Dermatol Ther. 2010;23:320-327.[Crossref] [PubMed] 
  10. Borges AS, Brasileiro A, Apetato M. Nodular vasculitis associated with lung adenocarcinoma. An Bras Dermatol. 2018;93:887-889.[Crossref] [PubMed] [PMC] 
  11. Khachemoune A, Longo MI, Phillips TJ. Nodular vasculitis as a paraneoplastic presentation? Int J Dermatol. 2003;42:639-642.[Crossref] [PubMed] 
  12. Haas B, Eckstein N, Pfeifer V, Mayer P, Hass MD. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes. 2014;4:e143.[Crossref] [PubMed] [PMC] 
  13. Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457-463.[Crossref] [PubMed] 
  14. Powell J, Garland SG. Ertugliflozin: a new option in the SGLT-2 inhibitor market for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2019;53:478-485.[Crossref] [PubMed] 
  15. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.[Crossref] [PubMed] 
  16. Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376:2300-2302.[Crossref] [PubMed] 
  17. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12:711-712.[Crossref] [PubMed] 
  18. To D, Bradshaw S, Lipson J. Case report of empagliflozin-induced cutaneous polyarteritis nodosa. J Cutan Med Surg. 2018;22:516-518.[Crossref] [PubMed]